000027760 000__ 03193cam\a2200457\i\4500
000027760 001__ 27760
000027760 003__ SzGeWIPO
000027760 005__ 20230626125643.0
000027760 008__ 161220s2016\\\\ne\\\\\\rb\\\\000\0\eng\\
000027760 020__ $$a9789079700851
000027760 035__ $$a(wipo)19417288
000027760 035__ $$a(OCoLC)965471047
000027760 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000027760 041__ $$aeng
000027760 050_4 $$aK1401$$b.H64 2016
000027760 08204 $$a346$$220
000027760 084__ $$aG 25 HOE.P
000027760 1001_ $$a’t Hoen, Ellen.
000027760 24510 $$aPrivate patents and public health :$$bchanging intellectual property rules for access to medicines.
000027760 264_1 $$aDiemen :$$bAMB Publishers,$$c2016.
000027760 300__ $$a181 pages ;$$c23 cm
000027760 336__ $$atext$$btxt$$2rdacontent
000027760 337__ $$aunmediated$$bn$$2rdamedia
000027760 338__ $$avolume$$bnc$$2rdacarrier
000027760 5050_ $$a1. Ending global diversity in patent laws: the trips agreement; 2. Turning the tide: the WTO DOHA declaration on trips & public health; 3. From declaration to application: the practical use of the DOHA declaration since 2001; 4. Closing the policy space: trade agreements and trips-plus measures; 5. The new frontiers: patents and treatment for cancer, hepatitis c, and other diseases; 6. Fixing the broken R&D system: ensuring essential innovation and access to medicines for all; 7. Restoring the balance: access to essential medicines in a post-trips world.
000027760 5208_ $$aMillions of people around the world do not have access to the medicines they need to treat disease or alleviate suffering. Strict patent regimes introduced following the establishment of the World Trade Organization in 1995 interfere with widespread access to medicines by creating monopolies that keep medicines prices well out of reach for many. 0The AIDS crisis in the late nineties brought access to medicines challenges to the public?s attention, when millions of people in developing countries died from an illness for which medicines existed, but were not available or affordable. Faced with an unprecedented health crisis? 8,000 people dying daily? the public health community launched an unprecedented global effort that eventually resulted in the large-scale availability of low-priced generic HIV medicines. 0But now, high prices of new medicines - for example, for cancer, tuberculosis and hepatitis C - are limiting access to treatment in low-, middle and high-income countries alike. Patent-based monopolies affect almost all medicines developed since 1995 in most countries, and global health policy is now at a critical juncture if the world is to avoid new access to medicines crises. 0This book discusses lessons learned from the HIV/AIDS crisis, and asks whether actions taken to extend access and save lives are exclusive to HIV or can be applied more broadly to new global access challenges.
000027760 650_0 $$aIntellectual property$$zDeveloping countries.
000027760 650_0 $$aDrugs$$xPatents.
000027760 650_0 $$aDrug accessibility$$zDeveloping countries.
000027760 650_0 $$aRight to health$$zDeveloping countries.
000027760 650_0 $$aIntellectual property.
000027760 650_0 $$aDrug accessibility.
000027760 650_0 $$aPharmaceutical policy.
000027760 650_0 $$aRight to health.
000027760 650_0 $$aPharmaceutical policy$$zDeveloping countries.
000027760 650_0 $$aPatents$$zDeveloping countries.
000027760 650_4 $$aPatents
000027760 650_4 $$aPublic health
000027760 651_0 $$aDeveloping countries$$xCommerce$$xLaw and legislation.
000027760 942__ $$2ddc$$cMON
000027760 952__ $$w2017-01-25$$p2017-0003$$u42281$$bMAIN$$10$$kG 25 HOE.P$$v2017-01-25$$zTagged$$70$$cLibrary
000027760 980__ $$aBIB
000027760 999__ $$c30208$$d30208